noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Company News

Locust Wood Capital Advisers LLC

Initial Quarterly Holdings Report by Institutional Manager (Form 13F-HR)
Citigroup Inc.

Primary Offering Prospectus (Form 424B2)
Nuveen Amt-Free Quality Municipal[...]

Notification of Call/Redemption of Securities by Closed-End Investment[...]

Pharmaceuticals and Biotechnology

Indivior Pharmaceuticals Inc.

11/03/2026 | Press release | Distributed by Public on 11/03/2026 08:11

Material Event (Form 8-K)

Item 8.01 Other.

Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the "Company" or the "Registrant") and U.S. Bank Trust Company, National Association (the "Indenture"), governing the Company's 0.625% Convertible Senior Notes due 2031 (the "Notes"), as a result of the Special Dividend that was declared by the Company's board on September 16, 2026, the conversion rate per $1,000 principal amount of Notes has been increased from 24.0033 shares of the Company's common stock to 30.9355 shares of the Company's common stock, which reflects a conversion price of approximately $32.33 per share. The conversion rate is subject to customary adjustments upon the occurrence of certain events as described in the Indenture. No bondholders converted their bonds for common stock.

Indivior Pharmaceuticals Inc. published this content on November 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 03, 2026 at 14:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]